CIISA-Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, Universidade de Lisboa, Avenida da Universidade Técnica, 1300-477, Lisbon, Portugal.
Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), 1300-477, Lisbon, Portugal.
Sci Rep. 2023 Jan 27;13(1):1559. doi: 10.1038/s41598-023-28845-0.
Topical instillation of drugs targeting the posterior ocular segment is an expanding area of research. Chitosan and hyaluronic acid have remarkable mucoadhesive properties and potentially enhance pre-corneal retention time after topical instillation. Bearing this in mind, we explored the possibility of delivering epoetin beta (EPOβ) to the posterior segment of the eye in a chitosan-hyaluronic acid (CS/HA-EPOβ) nanoparticulate system using the topical route of administration. Complete ophthalmological examinations, electroretinography and microhematocrit evaluations were performed in Wistar Hannover (WH) rats, before and after topical administration of nanoparticles. The right eye received CS/HA-EPOβ and the left eye received only empty nanocarriers (control). Animals were split into 6 groups and at designated timepoints, all animals from each group (n = 3) were euthanized and both eyes enucleated. Retinal morphology and EPOβ ocular distribution were assessed, respectively, through hematoxylin and eosin (HE) and immunofluorescence staining. After topical administration, no adverse ocular signs were noted and no significant changes either in microhematocrits nor in electroretinographies were detected. During the study, intraocular pressure (IOP) was always kept within physiological range bilaterally. No histological changes were detected in any of the ocular globes. Immunofluorescence enabled the identification of EPOβ in the retina 12 h after the administration, its presence still being detectable at day 21. In conclusion, CS/HA nanoparticles could efficiently deliver EPOβ to the retina of WH rats after topical instillation, being considered biologically safe. Topical administration of this nanoformulation could be a valuable tool for retinal neuroprotection, decreasing risks associated with more invasive routes of administration, being cost effective and also increasing long-term patients' compliance.
局部眼后段药物滴注是一个正在不断发展的研究领域。壳聚糖和透明质酸具有显著的黏膜黏附特性,并且可能会增加局部滴注后的角膜前滞留时间。考虑到这一点,我们探讨了通过局部途径将促红细胞生成素β(EPOβ)递送至壳聚糖-透明质酸(CS/HA-EPOβ)纳米颗粒系统的后眼段的可能性。在 Wistar Hannover(WH)大鼠中进行了全面的眼科检查、视网膜电图和微血球比容评估,在局部给予纳米颗粒之前和之后。右眼接受 CS/HA-EPOβ,左眼仅接受空纳米载体(对照)。动物分为 6 组,在指定的时间点,每组的所有动物(n=3)均被安乐死,并且双眼被摘除。通过苏木精和伊红(HE)和免疫荧光染色分别评估视网膜形态和 EPOβ的眼部分布。局部给药后,未观察到眼部不良体征,也未检测到微血球比容或视网膜电图有任何显著变化。在研究过程中,双眼的眼内压(IOP)始终保持在生理范围内。任何眼球均未发现组织学变化。免疫荧光使我们能够在给药后 12 小时在视网膜中识别 EPOβ,其在第 21 天仍可检测到。总之,CS/HA 纳米颗粒可以通过局部滴注有效地将 EPOβ递送至 WH 大鼠的视网膜,被认为具有生物安全性。该纳米制剂的局部给药可能是视网膜神经保护的有价值工具,可以降低与更具侵袭性的给药途径相关的风险,具有成本效益,并且还可以提高长期患者的依从性。